Emmanuel Papadakis
Stock Analyst at Deutsche Bank
(1.77)
# 3,354
Out of 5,127 analysts
41
Total ratings
45%
Success rate
0.24%
Average return
Main Sectors:
Stocks Rated by Emmanuel Papadakis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Buy | n/a | $48.63 | - | 5 | Sep 2, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $95 → $150 | $108.93 | +37.70% | 9 | Sep 19, 2024 | |
| MRNA Moderna | Upgrades: Hold | $85 → $80 | $42.00 | +90.50% | 8 | Aug 6, 2024 | |
| GRFS Grifols | Downgrades: Sell | n/a | $9.20 | - | 2 | Mar 12, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $193.40 | - | 3 | Feb 8, 2024 | |
| ALVO Alvotech | Maintains: Hold | $8 → $12 | $5.20 | +130.77% | 2 | Mar 7, 2023 | |
| NVO Novo Nordisk | Upgrades: Buy | n/a | $49.12 | - | 4 | Mar 16, 2022 | |
| NVS Novartis AG | Downgrades: Sell | n/a | $158.20 | - | 3 | Sep 20, 2021 | |
| ARGX argenx SE | Initiates: Hold | n/a | $833.16 | - | 1 | Jul 23, 2021 | |
| GSK GSK plc | Downgrades: Sell | n/a | $58.82 | - | 4 | Feb 4, 2021 |
Sanofi
Sep 2, 2025
Upgrades: Buy
Price Target: n/a
Current: $48.63
Upside: -
BioNTech SE
Sep 19, 2024
Maintains: Buy
Price Target: $95 → $150
Current: $108.93
Upside: +37.70%
Moderna
Aug 6, 2024
Upgrades: Hold
Price Target: $85 → $80
Current: $42.00
Upside: +90.50%
Grifols
Mar 12, 2024
Downgrades: Sell
Price Target: n/a
Current: $9.20
Upside: -
AstraZeneca
Feb 8, 2024
Downgrades: Hold
Price Target: n/a
Current: $193.40
Upside: -
Alvotech
Mar 7, 2023
Maintains: Hold
Price Target: $8 → $12
Current: $5.20
Upside: +130.77%
Novo Nordisk
Mar 16, 2022
Upgrades: Buy
Price Target: n/a
Current: $49.12
Upside: -
Novartis AG
Sep 20, 2021
Downgrades: Sell
Price Target: n/a
Current: $158.20
Upside: -
argenx SE
Jul 23, 2021
Initiates: Hold
Price Target: n/a
Current: $833.16
Upside: -
GSK plc
Feb 4, 2021
Downgrades: Sell
Price Target: n/a
Current: $58.82
Upside: -